Home
Clinical Trials
A Study Of Avelumab In Combin...

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

Last Updated: 2024-07-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

409 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-09

Study Completion Date

2023-03-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors. The primary purpose is to assess the safety and early signs of efficacy of various avelumab combinations with other cancer immunotherapies, optimizing dosing regimens as appropriate, in a limited series of indications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

NCT03010176

Solid Tumors Lymphoma

COMPLETED PHASE1

Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma

NCT00438581

Non-Hodgkin's Lymphoma

UNKNOWN PHASE2

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL

NCT00732498

Lymphoma

COMPLETED PHASE2

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

NCT03629756

Non-small Cell Lung Cancer Squamous Cell Carcinoma of the Head and Neck Breast Cancer +9 more

COMPLETED PHASE1

Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma

NCT00038623

Lymphoma, Mantle-Cell

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 1b/2, open-label, multi-center, multiple-dose, safety, clinical activity, PK, and PD study of avelumab in combination with other immune modulators in adult patients with locally advanced or metastatic solid tumors (eg, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple-negative breast cancer (TNBC), gastric cancer, platinum resistant ovarian cancer, bladder cancer, small cell lung cancer (SCLC) and progressing tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT/PVNS) . In Phase 1b, this includes patients whose disease has progressed on standard of care therapy or for whom no standard therapy is available. In Phase 2, enrollment criteria regarding prior treatment(s) received varies by tumor type. Incorporation of the other immune modulators into this study is based on preclinical and clinical data supportive of single-agent tolerability and potential clinical benefit, as well as non-clinical data suggesting safety, tolerability and clinical benefit of the agent(s) in combination with avelumab. Combinations of avelumab plus other immune modulator(s) to be evaluated are as follows:

* Combination A: avelumab plus utomilumab (4-1BB agonist mAb)
* Combination B: avelumab plus PF-04518600 (OX40 agonist mAb)
* Combination C: avelumab plus PD 0360324 (M-CSF mAb)
* Combination D: avelumab plus utomilumab plus PF-04518600
* Combination F: avelumab plus CMP-001 (TLR9 agonist) and avelumab plus CMP-001 plus utomilumab and avelumab plus CMP-001 and PF-04518600 Each combination will be studied individually in 2 study parts: 1) a Phase 1b Lead-in part to evaluate safety, and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and RP2D (if applicable), of the combination, and 2) a Phase 2 part to evaluate efficacy and further evaluate safety of the selected dose from the Phase 1b portion in pre-specified patient populations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort A1

NSCLC patients treated with avelumab + utomilumab (Dose level 1)

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

Utomilumab

Intervention Type DRUG

Anti-4-1BB antibody

Cohort A2

NSCLC patients treated with avelumab + utomilumab (Dose level 2)

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

Utomilumab

Intervention Type DRUG

Anti-4-1BB antibody

Cohort A3

NSCLC patients treated with avelumab + utomilumab (Dose level 3)

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

Utomilumab

Intervention Type DRUG

Anti-4-1BB antibody

Cohort A4

Melanoma patients treated with avelumab +utomilumab

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

Utomilumab

Intervention Type DRUG

Anti-4-1BB antibody

Cohort A5

SCCHN patients treated with avelumab + utomilumab

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

Utomilumab

Intervention Type DRUG

Anti-4-1BB antibody

Cohort A6

TNBC patients treated with avelumab + utomilumab

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

Utomilumab

Intervention Type DRUG

Anti-4-1BB antibody

Cohort A7

SCLC that has progressed after at least 1 line of platinum-containing therapy treated with avelumab +utomilumab

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

Utomilumab

Intervention Type DRUG

Anti-4-1BB antibody

Cohort A8

NSCLC first-line Stage IV treated with avelumab +PF-05082566

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

Utomilumab

Intervention Type DRUG

Anti-4-1BB antibody

Combination B Dose Escalation

PF-04518600 + avelumab in selected tumor types

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

PF-04518600

Intervention Type DRUG

OX40 Agonist

Combination B Expansion Cohorts

PF-04518600 + avelumab in selected tumor types

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

PF-04518600

Intervention Type DRUG

OX40 Agonist

Combination C Dose escalation cohorts

PD 0360324 + avelumab in selected tumor types

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

PD 0360324

Intervention Type DRUG

Anti-M-CSF

Combination C Dose expansion cohorts

PD 0360324 + aveluamb in selected tumor types

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

PD 0360324

Intervention Type DRUG

Anti-M-CSF

Combination D Dose escalation cohorts

PF-05082566 + PF-04518600 + avelumab in selected tumor types

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

Utomilumab

Intervention Type DRUG

Anti-4-1BB antibody

PF-04518600

Intervention Type DRUG

OX40 Agonist

Combination D Dose expansion cohorts

PF-05082566 + PF-04518600 + avelumab in selected tumor types

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

Utomilumab

Intervention Type DRUG

Anti-4-1BB antibody

PF-04518600

Intervention Type DRUG

OX40 Agonist

Cohort A9

NSCLC first-line Stage IV treated with avelumab +utomilumab (sequential starting with utomilumab monotherapy followed by combination)

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

Utomilumab

Intervention Type DRUG

Anti-4-1BB antibody

Cohort A10

NSCLC first-line Stage IV treated with avelumab + utomilumab (sequential starting with avelumab monotherapy followed by combination)

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

Utomilumab

Intervention Type DRUG

Anti-4-1BB antibody

Cohort F1

CMP-001 +avelumab in SCCHN

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

CMP-001

Intervention Type DRUG

TLR9 agonist

Cohort F2

CMP-001+avelumab+utomilumab in SCCHN

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

Utomilumab

Intervention Type DRUG

Anti-4-1BB antibody

CMP-001

Intervention Type DRUG

TLR9 agonist

Cohort F3

CMP-001 +avelumab+PF-04518600 in SCCHN

Group Type EXPERIMENTAL

Avelumab

Intervention Type DRUG

Anti-PD-L1 antibody

PF-04518600

Intervention Type DRUG

OX40 Agonist

CMP-001

Intervention Type DRUG

TLR9 agonist

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Avelumab

Anti-PD-L1 antibody

Intervention Type DRUG

Utomilumab

Anti-4-1BB antibody

Intervention Type DRUG

PF-04518600

OX40 Agonist

Intervention Type DRUG

PD 0360324

Anti-M-CSF

Intervention Type DRUG

CMP-001

TLR9 agonist

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MSB0010718C PF-05082566

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histological or cytological diagnosis of advanced/metastatic solid tumor. Measurable disease by RECIST 1.1 with at least 1 measurable lesion that has not been previously irradiated. Availability of tumor specimen taken within 1 year prior to study entry, with no intervening systemic anti-cancer therapy. No prior PD-1/PDL-1 therapy allowed. Combination A: Phase 1b, patients with NSCLC that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, SCCHN, TNBC in any line of therapy, SCLC, 1st line NSCLC. 1st line NSCLC must demonstrate to express PD-L1. Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination B: Phase 1b, patients with advanced solid tumors (NSCLC, SCCHN, melanoma) that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, or SCCHN. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination C: Ovarian cancer, SCCHN, NSCLC, gastric cancer, platinum resistant ovarian cancer. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. TGCT/PVNS that is either inoperable or requires extensive resection. Prior treatment with agents targeting CSF-1/CSF-1R not allowed. NSCLC activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination D: NSCLC, melanoma, SCCHN, bladder cancer. NSCLC activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. Combination F: Recurrent or metastatic SCCHN. One to three prior lines of systemic therapy for advanced stage or metastatic disease. Patients must have received anti PD-1/PD-L1 containing therapy (requires at least two doses of PD-1/PD-L1 agent).Disease progression no earlier than 6 weeks from initiation of the latest anticancer therapy. Evidence of radiologic progression is required. • Patient must be a candidate for intralesional administration with at least one tumor lesion which can be injected safely.
* ECOG performance status 0 or 1
* Estimated life expectancy of at least 3 months
* Adequate bone marrow, renal, and liver function
* Resolved acute effects of prior therapy
* Negative serum pregnancy test at screening
* Male and female patients able to have children must agree to use at least 1 highly effective method of contraception throughout the study and for at least 90 days after last dose
* Signed and dated informed consent

Exclusion Criteria

* Monoclonal antibody based anti-cancer therapy within 28 days prior to study entry or small-molecule based anti-cancer therapy (targeted therapy or chemotherapy) within 14 days prior to study entry. Combination F:PD-1/PD-L1 agent within 14 days prior study entry.
* Current or prior use of immunosuppressive medication within 7 days prior to study entry
* Active autoimmune disease requiring systemic steroids or immunosuppressive agents within 7 days prior to study entry
* Known prior or suspected hypersensitivity to investigational products
* Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry
* Patients with known symptomatic brain metastases requiring steroids
* Previous high-dose chemotherapy requiring stem cell rescue
* Prior allogeneic stem cell transplant or organ graft
* Any of the following within 6 months prior to study entry: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack
* Symptomatic pulmonary embolism within 6 months prior to study entry
* Known HIV or AIDS-related illness
* Active infection requiring systemic therapy
* Positive HBV or HCV test indicating acute or chronic infection
* Administration of a live vaccine within 4 weeks prior to study entry
* Diagnosis of other malignancy within 5 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix, or low-grade (Gleason ≤6) prostate cancer
* Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation
* Persisting toxicity related to prior therapy \>Grade 1
* Other severe acute or chronic medical condition
* Combo C :Existing periorbital edema.
* Combo C : Hypocalcemia, clinically significant bone disease or recent bone fracture (within 12 weeks prior study entry)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UCSD Medical Center - Encinitas

Encinitas, California, United States

Site Status

Koman Family Outpatient Pavilion

La Jolla, California, United States

Site Status

UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)

La Jolla, California, United States

Site Status

UC San Diego Perlman Medical Offices

La Jolla, California, United States

Site Status

UC San Diego Moores Cancer Center

La Jolla, California, United States

Site Status

UCLA Clinical Research Unit (Adminstration Office)

Los Angeles, California, United States

Site Status

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

Site Status

UCLA Hematology-Oncology Clinic

Los Angeles, California, United States

Site Status

UCLA Hematology-Oncology Infusion Center

Los Angeles, California, United States

Site Status

UC San Diego Medical Center - Hillcrest

San Diego, California, United States

Site Status

UCSD Medical Center - Vista

Vista, California, United States

Site Status

Georgetown University Medical Center

Washington D.C., District of Columbia, United States

Site Status

Mount Sinai Comprehensive Cancer Center - Aventura

Aventura, Florida, United States

Site Status

Mount Sinai Comprehensive Cancer Center

Miami Beach, Florida, United States

Site Status

Florida Cancer Specialists

Sarasota, Florida, United States

Site Status

H Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, United States

Site Status

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Site Status

University of Michigan Hospitals

Ann Arbor, Michigan, United States

Site Status

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Investigational Pharmacy, Karmanos Cancer Center

Detroit, Michigan, United States

Site Status

Karmanos Cancer Institute

Detroit, Michigan, United States

Site Status